Staging of non-metastatic nasopharyngeal carcinoma with PET/CT.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42009870.
- Also identified by DOI 10.1007/s00330-026-12537-0.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To evaluate the prognostic accuracy and clinical applicability of the ninth edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) tumor-node-metastasis (TNM) staging system for non-metastatic nasopharyngeal carcinoma (NPC) in the era of [<sup>18</sup>F]-fluorodeoxyglucose ([<sup>18</sup>F] FDG) positron emission tomography (PET)/computed tomography (CT). This retrospective study included 301 patients with NPC treated by intensity-modulated radiotherapy at a tertiary academic cancer center from January 1, 2003, to February 28, 2023. The comparison between the ninth edition of the AJCC/UICC TNM (TNM-9) and the eighth edition of the AJCC/UICC TNM (TNM-8) staging systems was performed. The primary endpoint was overall survival (OS). The proportions of patients receiving [<sup>18</sup>F] FDG PET/CT and magnetic resonance imaging as initial workup were 99.3% (299/301) and 96.9% (289/301), respectively. The median follow-up time was 88.1 months (interquartile range (IQR), 51.1-136.8 months). Based on the TNM-9 staging system, the 5-year OS rates of patients with Stage I, II and III were 91.7%, 84.8% and 76.8%, respectively (p = 0.090). The 5-year OS rates of patients with classification N0, N1, N2, and N3 were 92.0%, 87.1%, 77.6% and 79.1%, respectively (p = 0.879). The area under the receiver-operator characteristic curve values of the TNM-9 and TNM-8 were 0.6239 and 0.6678 for OS (p = 0.0003), respectively. The TNM-9 staging system did not exhibit strong overall discrimination between the stage-group classifications for OS of non-metastatic NPC in the [<sup>18</sup>F]FDG PET era. Question Does the newly launched TNM-9 staging system (January 2025) remain valid for non-metastatic NPC in the era of [<sup>18</sup>F] FDG PET/CT? Findings The TNM-9 staging system showed declining 5-year overall survival rates from Stage I to III, with modest overall predictive accuracy for overall survival. Clinical relevance These findings suggest that the TNM-9 staging system has a limited ability to discriminate overall survival between stage groups in non-metastatic NPC in the [<sup>18</sup>F] FDG PET/CT era.